Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
This article was originally published in PharmAsia News
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
You may also be interested in...
The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.
Since October, reported cases of infectious respiratory diseases have been rising in China, prompting an information request from the WHO. However, no new types of pathogen or unusual clinical symptoms have been detected so far.